Oteseconazole (VT-1161)
PreclinicalSmall molecule
Oteseconazole (VT-1161) is one of 7 small molecule programs targeting Vulvovaginal Candidiasis. It is currently in Preclinical.
1
Indications
4
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Vulvovaginal Candidiasis
#DrugCompanyPhaseTrials
1Lotrimin
BayerApproved
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Nizoral
WWim Janssens
Approved
Terazol 3
WWim Janssens
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Oteseconazole (VT-1161)
MMycovia Pharmaceuticals Inc.
Preclinical
Azole Antifungal
AAssiut University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Candidiasis2 trials
Vulvovaginal Candidiasis1 trial
Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC）
Not yet recruiting·—··NCT07044947·3,000 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oteseconazole (VT-1161). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMycovia Pharmaceuticals Inc.